{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:26Z","timestamp":1792427786854,"version":"4.5.0"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.critrevonc.2026.105169","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:23:30Z","timestamp":1769901810000},"page":"105169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Shaping immunotherapy through the tumor microenvironment: Translational perspectives"],"prefix":"10.1016","volume":"220","author":[{"given":"Vansh","family":"Vohra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Dhanawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Chalotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Garima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashan","family":"Girdhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inamul Hasan","family":"Madar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randhir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.critrevonc.2026.105169_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104471","article-title":"Advancements in tumor-infiltrating lymphocytes: historical insights, contemporary milestones, and future directions in oncology therapy","volume":"202","author":"Aizaz","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105169_bib3","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","article-title":"Epigenetic strategies to boost CAR T cell therapy","volume":"29","author":"Akbari","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105169_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarr\u00e1n","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105169_bib5","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.3390\/ijms21093238","article-title":"Tumor endothelial cell\u2014a biological tool for translational cancer research","volume":"21","author":"Annan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105169_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-030-37184-5_3","article-title":"Tumor microenvironment - non-hematopoietic cells","volume":"1234","author":"Atiya","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104143","article-title":"Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms","volume":"82","author":"Aung","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105169_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110632","article-title":"Naive primary neutrophils play a dual role in the tumor microenvironment","volume":"27","author":"Babatunde","year":"2024","journal-title":"IScience"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250103","article-title":"Microenvironmental signals shaping NK-cell reactivity in cancer","volume":"53","author":"Balzasch","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/ijms22041623","article-title":"Impact of Microbial Metabolites on Microbiota\u2013Gut\u2013Brain Axis in Inflammatory Bowel Disease","volume":"22","author":"Banfi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2120676","article-title":"Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness","volume":"11","author":"Barnestein","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105169_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00709","article-title":"Hepatic Stellate Cells and Hepatocarcinogenesis","volume":"8","author":"Barry","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105169_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cbpa.2020.02.005","article-title":"Advances in theranostic biomarkers for tumor immunotherapy","volume":"56","author":"Bellesoeur","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105169_bib16","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.3390\/cancers13174387","article-title":"Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma","volume":"13","author":"Borgia","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105169_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/bs.acr.2019.03.005","article-title":"Impact of the microbiome on cancer progression and response to anti-cancer therapies","volume":"143","author":"Buchta Rosean","year":"2019","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-025-06403-8","article-title":"Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial","volume":"23","author":"Bulgarelli","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: Perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2378520","article-title":"Human NK cells and cancer","volume":"13","author":"Cantoni","year":"2024","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202409898","article-title":"Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine","volume":"12","author":"Cassani","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105169_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104135","article-title":"Immunotherapy-related biomarkers: Confirmations and uncertainties","volume":"192","author":"Catalano","year":"2023","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.crbiot.2024.100177","article-title":"The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines","volume":"7","author":"Chakraborty","year":"2024","journal-title":"Curr. Res. Biotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib24","article-title":"Nanrilkefusp alfa (SOT101), an IL-15 receptor \u03b2\u03b3 superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers","volume":"6","author":"Champiat","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.894315","article-title":"\u03b3\u03b4 T Cells in the Tumor Microenvironment\u2014Interactions With Other Immune Cells","volume":"13","author":"Chan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104644","article-title":"Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases","volume":"93","author":"Chatziioannou","year":"2023","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70095","article-title":"Exosomes: a double-edged sword in cancer immunotherapy","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.critrevonc.2026.105169_bib29","article-title":"Unveiling tumor immune evasion mechanisms: abnormal expression of transporters on immune cells in the tumor microenvironment","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib30","article-title":"Platelets in the tumor microenvironment and their biological effects on cancer hallmarks","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105169_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.matbio.2023.07.003","article-title":"The extracellular matrix \u2013 immune microenvironment crosstalk in cancer therapy: Challenges and opportunities","volume":"121","author":"Closset","year":"2023","journal-title":"Matrix Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105169_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-024-06976-0","article-title":"Natural Killer cells at the frontline in the fight against cancer","volume":"15","author":"Co\u00ebnon","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2023.2173175","article-title":"Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement","volume":"23","author":"Colciago","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5, 2010","key":"10.1016\/j.critrevonc.2026.105169_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jhep.2014.02.003","article-title":"Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma","volume":"60","author":"Coulouarn","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib37","first-page":"45","article-title":"An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments","volume":"117","author":"Coxon","year":"2020","journal-title":"Mo. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105169_bib38","article-title":"Mimicking and analyzing the tumor microenvironment. Cell Reports","volume":"4","author":"Crouigneau","year":"2024","journal-title":"Methods"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105169_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102475","article-title":"Emerging technologies provide insights on cancer extracellular matrix biology and therapeutics","volume":"24","author":"Cruz-Acu\u00f1a","year":"2021","journal-title":"IScience"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105169_bib40","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3390\/cells10102617","article-title":"Exosomes in the Tumor Microenvironment: From Biology to Clinical Applications","volume":"10","author":"Da Costa","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105169_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155534","article-title":"Participation of T cells in generating immune protection against cancers","volume":"262","author":"Deo","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.critrevonc.2026.105169_bib43","article-title":"Current advances in immunotherapy for cancer","volume":"12","author":"Desai","year":"2024","journal-title":"Oral. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib44","article-title":"Role of the Extracellular Matrix in Cancer: Insights into Tumor Progression and Therapy","volume":"8","author":"Desai","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105169_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216894","article-title":"Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies","volume":"591","author":"El-Tanani","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105169_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/03946320231158025","article-title":"Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy","volume":"37","author":"Erlandsson","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib47","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib48","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2007-05-091306","article-title":"Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells","volume":"110","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105169_bib49","article-title":"Computational cancer neoantigen prediction: current status and recent advances","volume":"12","author":"Fotakis","year":"2021","journal-title":"ImmunoOncol. Technol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib50","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105169_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105169_bib54","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-023-04418-7","article-title":"Eosinophils in the tumor microenvironment: implications for cancer immunotherapy","volume":"21","author":"Ghaffari","year":"2023","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib56","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105169_bib58","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105169_bib59","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/all.15751","article-title":"Eosinophils from A to Z","volume":"78","author":"Gigon","year":"2023","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105169_bib60","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8+ T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","article-title":"Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy","volume":"45","author":"Guo","year":"2024","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.733800","article-title":"Control of Dendritic Cell Function Within the Tumour Microenvironment","volume":"13","author":"Gupta","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib63","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The Platelet Lifeline to Cancer: Challenges and Opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105169_bib66","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.critrevonc.2026.105169_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy","volume":"6","author":"Henke","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib68","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI95148","article-title":"Mechanisms and functions of cellular senescence","volume":"128","author":"Herranz","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105169_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104588","article-title":"Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions","volume":"206","author":"Hsu","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib70","first-page":"1","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105169_bib71","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1002\/cam4.3466","article-title":"Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis","volume":"9","author":"Huang","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-030-49270-0_5","article-title":"\u03b3\u03b4 T cells in tumor microenvironment","volume":"1273","author":"Imbert","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7418","article-title":"Lymphocyte activation markers predict the therapeutic response to immune checkpoint inhibitors: a case\u2013control study","volume":"13","author":"Iwamoto","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104826","article-title":"Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing","volume":"97","author":"Jagatia","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105169_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2019.11.002","article-title":"Natural killer cells: diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis","volume":"16","author":"Jewett","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216074","article-title":"Pericytes in the tumor microenvironment","volume":"556","author":"Jiang","year":"2023","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib79","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/agm2.12295","article-title":"Tumor neoantigens and tumor immunotherapies","volume":"7","author":"Jiani","year":"2024","journal-title":"Aging Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1025218","article-title":"Exosomes in the tumor microenvironment: Promoting cancer progression","volume":"13","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib81","article-title":"Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy","volume":"5","author":"Kang","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115432","article-title":"The tumor microenvironment is an ecosystem sustained by metabolic interactions","volume":"44","author":"Kay","year":"2025","journal-title":"Cell Rep."},{"issue":"10391","key":"10.1016\/j.critrevonc.2026.105169_bib83","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/cells12030365","article-title":"Epigenetic perspective of immunotherapy for cancers","volume":"12","author":"Keshari","year":"2023","journal-title":"Cells"},{"issue":"7738","key":"10.1016\/j.critrevonc.2026.105169_bib85","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105169_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cas.13498","article-title":"Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens","volume":"109","author":"Kiyotani","year":"2018","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105169_bib88","doi-asserted-by":"crossref","first-page":"9765","DOI":"10.1136\/jitc-2024-009765","article-title":"Dendritic cells pulsed with multifunctional Wilms\u2019 tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer","volume":"12","author":"Koido","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","article-title":"Role of mast cells in shaping the tumor microenvironment","volume":"58","author":"Komi","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105169_bib91","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/eji.201948470","article-title":"Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer","volume":"50","author":"Kurniawan","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib92","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib93","article-title":"Phenotypic and functional properties of tumor-infiltrating regulatory T cells","volume":"2017","author":"Lee","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105169_bib95","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105169_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1367875","article-title":"Endothelial cells in tumor microenvironment: insights and perspectives","volume":"15","author":"Leone","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105169_bib97","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1085-0","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0975-5","article-title":"Exosomes in the tumor microenvironment as mediators of cancer therapy resistance","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105169_bib100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pharmthera.2019.04.005","article-title":"Mesenchymal stem cells: From regeneration to cancer","volume":"200","author":"Li","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib101","first-page":"1","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105169_bib102","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221076194","article-title":"Molecular imaging of tumor-associated macrophages in cancer immunotherapy","volume":"14","author":"Li","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib103","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-6-1","article-title":"The potential and promise for clinical application of adoptive T cell therapy in cancer","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/1758194X.2024.2370228","article-title":"Tumor immune microenvironment and response of immunotherapy in patients with colorectal cancer","volume":"13","author":"Liao","year":"2024","journal-title":"Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2026.105169_bib106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.iotech.2020.03.001","article-title":"Molecular imaging for cancer immunotherapy","volume":"5","author":"Lim","year":"2020","journal-title":"ImmunoOncol. Technol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib107","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib108","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","article-title":"Releasing the brakes on cancer immunotherapy","volume":"162","author":"Littman","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105169_bib109","article-title":"Clinical cancer immunotherapy: current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115142","article-title":"Why treg should be the focus of cancer immunotherapy: the latest thought","volume":"168","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105169_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2017.12.003","article-title":"Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance","volume":"110","author":"Long","year":"2019","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib112","article-title":"Comprehensive analysis of tumor-infiltrating immune cells and relevant therapeutic strategy in esophageal cancer","volume":"2020","author":"Lu","year":"2020","journal-title":"Dis. Markers"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105169_bib113","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib114","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"LV","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1400","article-title":"Modelling the tumor immune microenvironment for precision immunotherapy","volume":"11","author":"Mackenzie","year":"2022","journal-title":"Clin. Transl. Immunol."},{"issue":"7693","key":"10.1016\/j.critrevonc.2026.105169_bib116","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-26225-8","article-title":"Simultaneous analysis of tumor-infiltrating immune cells density, tumor budding status, and presence of lymphoid follicles in CRC tissue","volume":"12","author":"Markowski","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105169_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692982","article-title":"Boosting antitumor response by costimulatory strategies driven to 4-1BB and OX40 T-cell receptors","volume":"9","author":"Mascarelli","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-49270-0_1","article-title":"Eosinophils in the Tumor Microenvironment","volume":"1273","author":"Mattei","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105169_bib120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","article-title":"The regulatory role of invariant NKT cells in tumor immunity","volume":"3","author":"McEwen-Smith","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105169_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104039","article-title":"Application of molecular imaging technology in tumor immunotherapy","volume":"348","author":"Meng","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104452","article-title":"An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers","volume":"88","author":"Mezheyeuski","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib123","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2014 elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05560-2","article-title":"Potential links between the microbiota and T cell immunity determine the tumor cell fate","volume":"14","author":"Mohseni","year":"2023","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105169_bib125","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"CD4+ T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105169_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1426033","article-title":"Pericytes: jack-of-all-trades in cancer-related inflammation","volume":"15","author":"Moro","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0344-8","article-title":"Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden","volume":"6","author":"Morrison","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41698-025-00885-x","article-title":"Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies","volume":"9","author":"Mortaja","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14737159.2022.2049244","article-title":"Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"22","author":"Muhammed","year":"2022","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105169_bib130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib131","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib132","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.it.2023.10.007","article-title":"Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies","volume":"44","author":"Nasir","year":"2023","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib133","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14737140.2020.1724539","article-title":"Predictive biomarkers of response to immune checkpoint inhibitors in melanoma","volume":"20","author":"Nebhan","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105169_bib134","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.3390\/cancers13205174","article-title":"The current landscape of NKT cell immunotherapy and the hills ahead","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib135","doi-asserted-by":"crossref","first-page":"10013","DOI":"10.1136\/jitc-2024-010013","article-title":"Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors","volume":"13","author":"Nelson","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105169_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353787","article-title":"Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy","volume":"15","author":"Nicolini","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib137","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105169_bib138","first-page":"9160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib139","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/JLB.4RI0818-311R","article-title":"Monocyte heterogeneity and functions in cancer","volume":"106","author":"Olingy","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"399","key":"10.1016\/j.critrevonc.2026.105169_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib141","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2017-0037","article-title":"Distribution of tumor-infiltrating immune cells in glioblastoma","volume":"7","author":"Orrego","year":"2018","journal-title":"CNS Oncol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-37184-5_1","article-title":"Adipocytes in the tumour microenvironment","volume":"1234","author":"Pallegar","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2025.100177","article-title":"Human \u03b3\u03b4 T cells in the tumor microenvironment: key insights for advancing cancer immunotherapy","volume":"48","author":"Park","year":"2025","journal-title":"Mol. Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15384047.2017.1394538","article-title":"Modulating secreted components of tumor microenvironment: a masterstroke in tumor therapeutics","volume":"19","author":"Patel","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105169_bib146","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers","volume":"14","author":"Pe\u00f1a-Romero","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105169_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103184","article-title":"How to select cancer patients for immunotherapy","volume":"63","author":"Pfeiffer","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105169_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291530","article-title":"Targeting vascular normalization: a promising strategy to improve immune\u2013vascular crosstalk in cancer immunotherapy","volume":"14","author":"Qian","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib149","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2015.10.022","article-title":"Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment","volume":"380","author":"Qu","year":"2016","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbm.2024.100068","article-title":"Tug of war: understanding the dynamic interplay of tumor biomechanical environment on dendritic cell function","volume":"2","author":"Quartey","year":"2024","journal-title":"Mechanobiol. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib151","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s13346-021-01040-2","article-title":"Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor\u2013loaded nanoparticle enhances anticancer efficacy","volume":"11","author":"Ramesh","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib152","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib153","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2038403","article-title":"What\u2019s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination","volume":"11","author":"Redwood","year":"2022","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib154","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib155","article-title":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific","volume":"6","author":"Sacco","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102329","article-title":"Tumor immune evasion through loss of MHC class-I antigen presentation","volume":"83","author":"Sari","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib157","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.crimmu.2021.08.002","article-title":"Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape","volume":"2","author":"Sarkar","year":"2021","journal-title":"Curr. Res. Immunol."},{"issue":"MAR","key":"10.1016\/j.critrevonc.2026.105169_bib158","first-page":"21442","article-title":"Molecular mechanisms oftreg-mediatedt cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-19-0041","article-title":"Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors","volume":"8","author":"Schramme","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105169_bib160","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188845","article-title":"Focus on mast cells in the tumor microenvironment: current knowledge and future directions","volume":"1878","author":"Shi","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) Reviews Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib162","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cam4.3550","article-title":"Predictive biomarkers for immune checkpoint inhibitors in metastatic breast cancer","volume":"10","author":"Sivapiragasam","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib163","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-030-37184-5_6","article-title":"Endothelial cells in the tumor microenvironment","volume":"1234","author":"Sobierajska","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib164","article-title":"The emerging roles of pericytes in modulating tumor microenvironment","volume":"9","author":"Sun","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105169_bib165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105169_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib167","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105169_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib169","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J. Extracell. Vesicles"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib170","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-024-02584-4","article-title":"Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications","volume":"22","author":"Tong","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib173","article-title":"Tumor Microenvironment: A New Treatment Target for Cancer","volume":"2014","author":"Tsai","year":"2014","journal-title":"Int. Sch. Res. Not."},{"issue":"7528","key":"10.1016\/j.critrevonc.2026.105169_bib174","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105169_bib175","article-title":"Myeloid derived suppressor cells in tumor microenvironment: interaction with innate lymphoid cells","volume":"61\u201364","author":"Tumino","year":"2022","journal-title":"Semin. Immunol."},{"issue":"16, 2021","key":"10.1016\/j.critrevonc.2026.105169_bib176","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-pathmechdis-012418-013058","article-title":"Monocytes in the tumor microenvironment","volume":"16","author":"Ugel","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib177","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105169_bib178","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/cam4.2327","article-title":"Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib179","article-title":"Advances in targeting tumor microenvironment for immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib180","article-title":"Cancer immunotherapies: from efficacy to resistance mechanisms \u2013 not only checkpoint matters","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib181","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.2147\/CMAR.S269773","article-title":"<p>Application and Prospects of Molecular Imaging in Immunotherapy<\/p>.","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105169_bib182","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"10427","key":"10.1016\/j.critrevonc.2026.105169_bib183","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105169_bib184","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41551-020-0524-y","article-title":"The expanding landscape of inflammatory cells affecting cancer therapy","volume":"4","author":"Weissleder","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105169_bib185","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib186","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semcancer.2012.03.004","article-title":"What are regulatory T cells (Treg) regulating in cancer and why?","volume":"22","author":"Whiteside","year":"2012","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib187","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastas.. Rev."},{"issue":"MAR","key":"10.1016\/j.critrevonc.2026.105169_bib188","article-title":"Novel approaches to exploiting invariant NKT cells in cancer immunotherapy","volume":"9","author":"Wolf","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib189","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.541","article-title":"The rising roles of exosomes in the tumor microenvironment reprogramming and cancer immunotherapy","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.critrevonc.2026.105169_bib190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.621937","article-title":"The role of stellate cells in pancreatic ductal adenocarcinoma: targeting perspectives","volume":"10","author":"Wu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105169_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105169_bib192","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.apsb.2022.11.001","article-title":"Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105169_bib193","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105169_bib194","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbamcr.2015.07.008","article-title":"The role of platelets in the tumor microenvironment: From solid tumors to leukemia","volume":"1863","author":"Yan","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) Molecular Cell Research"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105169_bib195","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105169_bib196","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113464","article-title":"Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: a burdensome journey to promising land","volume":"153","author":"Yu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib198","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ird3.12","article-title":"Molecular imaging for cancer immunotherapy","volume":"1","author":"Yu","year":"2023","journal-title":"IRADIOLOGY"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib199","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.it.2023.02.006","article-title":"Exhausted CD8+ T cells face a developmental fork in the road","volume":"44","author":"Zander","year":"2023","journal-title":"Trends Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105169_bib200","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.3390\/ijms25147509","article-title":"Enhancing dendritic cell cancer vaccination: the synergy of immune checkpoint inhibitors in combined therapies","volume":"25","author":"Zanotta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105169_bib201","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105169_bib202","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105169_bib203","doi-asserted-by":"crossref","first-page":"923","DOI":"10.20892\/j.issn.2095-3941.2020.0338","article-title":"Exhausted T cells and epigenetic status","volume":"17","author":"Zeng","year":"2020","journal-title":"Cancer Biol. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105169_bib204","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1111\/febs.15028","article-title":"The influence of microenvironment on tumor immunotherapy","volume":"286","author":"Zhang","year":"2019","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-024-06014-9","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development?","volume":"16","author":"Zhao","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105169_bib206","first-page":"237","article-title":"Biomimetic manganese-based theranostic nanoplatform for cancer multimodal imaging and twofold immunotherapy","volume":"19","author":"Zhao","year":"2023","journal-title":"Bioact. Mater."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105169_bib207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105169_bib208","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105169_bib209","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.arcmed.2022.11.001","article-title":"Mesenchymal stem\/stromal cells in cancer: from initiation to metastasis","volume":"53","author":"Zheng","year":"2022","journal-title":"Arch. Med. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105169_bib210","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-023-40826-5","article-title":"Theranostic imaging and multimodal photodynamic therapy and immunotherapy using the mTOR signaling pathway","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105169_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103137","article-title":"Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: a multidimensional analysis","volume":"63","author":"Zou","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:56:46Z","timestamp":1776974206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":211,"alternative-id":["S1040842826000569"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105169","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shaping immunotherapy through the tumor microenvironment: Translational perspectives","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105169"}}